Clinical trials: Botulinum Toxin
Glabellar Frown Lines
The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase I/II clinical trials. In Phase I, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at…
- Trial name
- NCT04996810
- Testing
- PROTOXIN, Botox®
- Where
- 2 sites in South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Migraine Disorders
BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine
This study will evaluate the efficacy and safety of BOTOX® (Botulinum Toxin Type A) compared with placebo as headache prophylaxis in Chinese participants with chronic migraine.
- Trial name
- NCT03193346
- Testing
- botulinum toxin Type A
- Sponsor
- Allergan
Upper Limb Spasticity
Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice
The primary purpose for this study is to understand the effect of botulinum toxin as a treatment integrated in the management of spasticity (stiffness) in the arm and/or hand, arising from any neurological condition.
- Trial name
- ULIS III (NCT02454803)
- Where
- 57 sites in United States, Australia and 12 more
- Volunteers
- 1,004 people
- Sponsor
- Ipsen
Hyperhidrosis, Muscle Spasticity
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal…
- Conditions
- Hyperhidrosis, Muscle Spasticity, Glabellar Lines
- Trial name
- NCT02043145
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 727 people
- Sponsor
- Allergan
Habitual Snoring
Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring
The purpose of this study is to identify out of up to three doses a safe and effective dose of Botulinum toxin type A for an injection into one side of the soft palate to treat snoring.
- Trial name
- NCT01515371
- Testing
- IncobotulinumtoxinA
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Merz Pharmaceuticals GmbH
Platysma Prominence
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
This is a Phase 3, open-label extension study to evaluate the long-term safety of repeat BOTOX treatments in adult participants with Platysma Prominence.
- Trial name
- NCT05134649
- Testing
- OnabotulinumtoxinA
- Where
- 29 sites in United States, Canada
- Volunteers
- 292 people
- Sponsor
- AbbVie
Cervical Dystonia
Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia
The goal of this retrospective, international, multi-center chart abstraction is to learn about the long-term impact of product-specific immunogenicity-related factors in different botulinum neurotoxin type A formulations in…
- Trial name
- RELY-CD (NCT05884528)
- Testing
- CC BoNT/A, CF BoNT/A, CF to CC BoNT/A
- Where
- Germany
- Volunteers
- 270 people
- Sponsor
- Merz Therapeutics GmbH
Urinary Incontinence, Overactive Bladder
A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India
This is a Post-Marketing Surveillance study in India to evaluate safety and efficacy of BOTOX® (Botulinum Toxin Type A) in the treatment of patients with urinary incontinence due to neurogenic detrusor overactivity or overactive…
- Trial name
- NCT02590250
- Testing
- botulinum toxin Type A
- Where
- 12 sites in India
- Volunteers
- 250 people
- Sponsor
- Allergan
Overactive Bladder
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910845
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 2 sites in United States, Canada
- Volunteers
- 557 people
- Sponsor
- Allergan
Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018).
- Trial name
- NCT05028569
- Testing
- BOTOX
- Where
- 133 sites in United States, Canada and 7 more
- Volunteers
- 775 people
- Sponsor
- AbbVie
Glabellar Frown Lines
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)
The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
- Trial name
- BLESSIII (NCT03985982)
- Testing
- Botulinum Toxin A
- Where
- United States
- Volunteers
- 410 people
- Sponsor
- Croma-Pharma GmbH
Skin Aging
Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
This study will confirm the efficacy and safety of a single topical administration of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines
- Trial name
- NCT01940991
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Revance Therapeutics, Inc.
Overactive Bladder
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910520
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 548 people
- Sponsor
- Allergan
Upper Limb Spasticity
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
This is a randomized, double-blind, multi-center phase II/III study to evaluate the efficacy and safety of Recombinant Botulinum Toxin Type A (YY001) for injection in the treatment of upper limb spasticity in adults
- Trial name
- NCT06783114
- Testing
- Recombinant Botulinum Toxin Type A for injection (YY001), BOTOX®
- Where
- 24 sites in China
- Volunteers
- 254 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Interstitial Cystitis, IC
Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients
The investigators believe that this study is of importance of several aspects: 1. It evaluates a new mode of bladder instillation that may bypass the drawbacks of the current instillation mode. 2.
- Trial name
- NCT01997983
- Testing
- TC-3 Gel mixed with Botox (BTX)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- UroGen Pharma Ltd.
Essential Tremor of the Upper Limbs
Botulinum Toxin A to Treat Arm Tremor
The objective of this study is to assess the efficacy and safety of a single, kinematic-analysis-based intramuscular injection of NT 201, compared with placebo, in moderate to marked essential tremor of the upper limb.
- Trial name
- NCT02207946
- Testing
- IncobotulinumtoxinA
- Where
- 6 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Merz Pharmaceuticals GmbH
Upper and/or Lower Limb Focal Spasticity
A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal Spasticity
The aim of this retrospective study is to describe the real-world outcomes with the treatment of adult patients with Dysport® injections for focal upper limb spasticity (ULS) and/or focal lower limb spasticity (LLS) in NHS…
- Trial name
- DYSCOVER (NCT04604379)
- Where
- 3 sites in United Kingdom
- Volunteers
- 123 people
- Sponsor
- Ipsen
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
This is a 60 week study including a double-blind phase followed by an open-label extension phase.
- Trial name
- NCT00156910
- Testing
- Botulinum Toxin Type A
- Where
- 2 sites in United States, Canada
- Volunteers
- 679 people
- Sponsor
- Allergan
Moderate to Severe Glabellar Lines
A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines
The study is a two-part (Part A and Part B) randomized double-blind vehicle-controlled multi-center study in a total of 174 participants with moderate to severe glabellar lines.
- Trial name
- NCT06481475
- Testing
- YY003, Vehicle Control
- Where
- 3 sites in Australia
- Volunteers
- 153 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Overactive Bladder
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis.
- Trial name
- NCT00876447
- Testing
- Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 397 people
- Sponsor
- Allergan